MedTrace Logo

VNRX-9945 Safety and Pharmacokinetics in Healthy Adult Volunteers

NCT04845321 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-06-10

No results posted yet for this study

Summary

This is a 2-part first-in-human dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-9945.

Conditions

  • Healthy Volunteers

Interventions

DRUG

VNRX-9945

Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)

DRUG

Placebo for VNRX-9945

Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)

Sponsors & Collaborators

  • Novotech (Australia) Pty Limited

    collaborator INDUSTRY

  • Venatorx Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-23
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04845321 on ClinicalTrials.gov